Cell and gene therapy

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Cell and gene therapies have been making the news this week, as we launch our very own guide to global innovation in CGT with the Winter […]

Register to attend Cell and gene therapy: sustaining growth and maximising opportunities, a free-to-attend DDW webinar, supported by Benchling and BPS Bioscience, on February 17, 2023 at 8am PST / 11am EST / 4pm GMT / 5pm CET.  Cell and gene therapies (CGT) are transforming the way diseases are treated. As research progresses it is […]

News round-up for 23-27 January by DDW Digital Content Editor Diana Spencer. Cell and gene therapies have been making the news this week, as we launch our very own guide to global innovation in CGT with the Winter issue of DDW, as well as an exciting new virtual event on the same topic.  The top stories:  Gene […]

Myosana Therapeutics has completed a seed funding round totalling over $5 million led by investor John Ballantyne.  The capital will go towards developing Myosana’s gene therapy platform for neuromuscular and cardiac disease, with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025.  “Built on decades of expertise in neuromuscular diseases, […]

The Winter 2022/2023 issue of Drug Discovery World Magazine is out now. Featuring a Therapeutic Spotlight on Oncology, the magazine is available to download free here and read for free on the DDW App. You can also request to receive a copy of the printed magazine here. Key features of the Winter issue include an overview of the drug […]

Cell and gene therapies (CGT) are transforming the way diseases are treated. As research progresses it is hoped that cell and gene therapies will offer innovation for the future. Join this free webinar, hosted by DDW and supported by BPS Bioscience and Benchling, to learn about the biggest challenges and opportunities facing the cell and […]

Cell and gene therapies are transforming the way diseases are treated. As research progresses it is hoped that cell and gene therapies will offer innovation for the future. In this free webinar on February 17, 2023 you will hear from CBO/CDO of Adthera Bio, Stuart Curbishley, Chief Executive Officer of Cell & Gene Therapy Catapult, […]

The European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to FBX-101, Forge Biologic’s adeno-associated virus (AAV) drug candidate for treating patients with Krabbe disease.  PRIME is a regulatory designation by the EMA that provides early and proactive support to developers of promising medicines, to advance and speed up their development and usher them […]

The European Commission has granted orphan designation for Krystal Biotech’s KB407 for the treatment of cystic fibrosis (CF).  KB407 is an investigational, redosable gene therapy designed to correct the underlying cause of cystic fibrosis by delivering two copies of the CFTR gene directly to the airway epithelial cells when delivered via a nebuliser.   By inducing […]

Download this exclusive cell and gene therapy guide to learn about: The successes of cell and gene therapies plus the biggest questions facing the sector Expert views on the challenges and opportunities for cell and gene therapies in 2023 Understanding future road maps of cell and gene therapies Why there are two sides to the […]